## Sanja Andric Petrovic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/271233/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
2	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	10.4	127
3	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	4.3	46
4	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	3.9	36
5	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	4.5	28
6	Phosphorylation of leukocyte glucocorticoid receptor in patients with current episode of major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 40, 281-285.	4.8	25
7	The acute and medium-term effects of treatment with electroconvulsive therapy on memory in patients with major depressive disorder. Psychological Medicine, 2016, 46, 797-806.	4.5	23
8	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
9	The emerging role of the FKBP5 gene polymorphisms in vulnerability–stress model of schizophrenia: further evidence from a Serbian population. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 527-539.	3.2	20
10	Prescribing practices in Southeastern Europe – focus on benzodiazepine prescription at discharge from nine university psychiatric hospitals. Psychiatry Research, 2017, 258, 59-65.	3.3	19
11	Familial covariation of facial emotion recognition and IQ in schizophrenia. Psychiatry Research, 2016, 246, 52-57.	3.3	18
12	Neuroticism and facial emotion recognition in healthy adults. Microbial Biotechnology, 2016, 10, 160-164.	1.7	17
13	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	4.5	14
14	Survey of the European Psychiatric Association on the European status and perspectives in early detection and intervention in atâ€risk mental state and firstâ€episode psychosis. Microbial Biotechnology, 2019, 13, 853-858.	1.7	11
15	Sex differences in facial emotion recognition in health and psychotic disorders. Cognitive Neuropsychiatry, 2019, 24, 108-122.	1.3	11
16	European status and perspectives on early detection and intervention in at-risk mental state and first episode psychosis: Viewpoint from the EPA section for prevention of mental disorders. European Psychiatry, 2017, 46, 48-50.	0.2	10
17	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	4.8	10
18	The role of glucocorticoid receptor phosphorylation in the model of negative affective states. World Journal of Biological Psychiatry, 2015, 16, 301-311.	2.6	8

#	Article	IF	CITATIONS
19	»Treatment Resistance« Enigma Resolved by Pharmacogenomics â~' A Case Study of Clozapine Therapy in Schizophrenia / Enigma »Terapo-Rezistence« Razrešena Uz Pomoć Farmakogenomike - Prikaz Slućaja Terapije Klozapinom U Shizofreniji. Journal of Medical Biochemistry, 2015, 34, 223-227.	1.7	7
20	The FKBP5 genotype and childhood trauma effects on FKBP5 DNA methylation in patients with psychosis, their unaffected siblings, and healthy controls. Psychoneuroendocrinology, 2021, 128, 105205.	2.7	7
21	Maintenance phase treatment of psychotic disorders in outpatients from Serbia – focus on long-term benzodiazepine use. International Journal of Psychiatry in Clinical Practice, 2020, 24, 315-321.	2.4	6
22	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	2.6	5
23	Implementation of early detection and intervention services for psychosis in Central and Eastern Europe: Current status. Microbial Biotechnology, 2019, 13, 1283-1288.	1.7	5
24	Executive function in treatment-resistant depression before and after electroconvulsive therapy. World Journal of Biological Psychiatry, 2017, 18, 624-632.	2.6	2
25	Openness to experience shortens duration of untreated psychosis in Serbian clinical population. Microbial Biotechnology, 2018, 12, 91-95.	1.7	2
26	The classification of psychotic disorders: Trending topics. Engrami, 2019, 41, 85-100.	0.1	1
27	S211. LONG-TERM BENZODIAZEPINE USE DURING MAINTENANCE THERAPY OF PSYCHOSIS - ASSOCIATION WITH SYMPTOMS, COGNITION AND FUNCTIONALITY. Schizophrenia Bulletin, 2020, 46, S119-S119.	4.3	0
28	Duration of psychiatric appointments for patients with Psychosis spectrum disorders in Serbia: Is it significantly prolonged by DIALOG+ psychosocial intervention?. Psihijatrija Danas, 2020, 52, 13-24.	0.1	0
29	Maintenance Therapy of Psychosis Spectrum Disorders in a Real-World Setting: Antipsychotics Prescription Patterns and Long-Term Benzodiazepine Use. Frontiers in Psychiatry, 2022, 13, 796719.	2.6	0